This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
2oiq
From Proteopedia
(New page: 200px<br /><applet load="2oiq" size="450" color="white" frame="true" align="right" spinBox="true" caption="2oiq, resolution 2.07Å" /> '''Crystal Structure of...) |
|||
| Line 1: | Line 1: | ||
| - | [[Image:2oiq.gif|left|200px]]<br /><applet load="2oiq" size=" | + | [[Image:2oiq.gif|left|200px]]<br /><applet load="2oiq" size="350" color="white" frame="true" align="right" spinBox="true" |
caption="2oiq, resolution 2.07Å" /> | caption="2oiq, resolution 2.07Å" /> | ||
'''Crystal Structure of chicken c-Src kinase domain in complex with the cancer drug imatinib.'''<br /> | '''Crystal Structure of chicken c-Src kinase domain in complex with the cancer drug imatinib.'''<br /> | ||
==Overview== | ==Overview== | ||
| - | The cancer drug imatinib inhibits the tyrosine kinases c-Abl, c-Kit, and | + | The cancer drug imatinib inhibits the tyrosine kinases c-Abl, c-Kit, and the PDGF receptor. Imatinib is less effective against c-Src, which is difficult to understand because residues interacting with imatinib in crystal structures of Abl and c-Kit are conserved in c-Src. The crystal structure of the c-Src kinase domain in complex with imatinib closely resembles that of Abl*imatinib and c-Kit*imatinib, and differs significantly from the inactive "Src/CDK" conformation of the Src family kinases. Attempts to increase the affinity of c-Src for imatinib by swapping residues with the corresponding residues in Abl have not been successful, suggesting that the thermodynamic penalty for adoption of the imatinib-binding conformation by c-Src is distributed over a broad region of the structure. Two mutations that are expected to destabilize the inactive Src/CDK conformation increase drug sensitivity 15-fold, suggesting that the free-energy balance between different inactive states is a key to imatinib binding. |
==About this Structure== | ==About this Structure== | ||
| - | 2OIQ is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Gallus_gallus Gallus gallus] with STI and GOL as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/Non-specific_protein-tyrosine_kinase Non-specific protein-tyrosine kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.10.2 2.7.10.2] Full crystallographic information is available from [http:// | + | 2OIQ is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Gallus_gallus Gallus gallus] with <scene name='pdbligand=STI:'>STI</scene> and <scene name='pdbligand=GOL:'>GOL</scene> as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/Non-specific_protein-tyrosine_kinase Non-specific protein-tyrosine kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.10.2 2.7.10.2] Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2OIQ OCA]. |
==Reference== | ==Reference== | ||
| - | c-Src | + | c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty., Seeliger MA, Nagar B, Frank F, Cao X, Henderson MN, Kuriyan J, Structure. 2007 Mar;15(3):299-311. PMID:[http://ispc.weizmann.ac.il//pmbin/getpm?pmid=17355866 17355866] |
[[Category: Gallus gallus]] | [[Category: Gallus gallus]] | ||
[[Category: Non-specific protein-tyrosine kinase]] | [[Category: Non-specific protein-tyrosine kinase]] | ||
| Line 16: | Line 16: | ||
[[Category: Cao, X.]] | [[Category: Cao, X.]] | ||
[[Category: Frank, F.]] | [[Category: Frank, F.]] | ||
| - | [[Category: Henderson, M | + | [[Category: Henderson, M N.]] |
[[Category: Kuriyan, J.]] | [[Category: Kuriyan, J.]] | ||
[[Category: Nagar, B.]] | [[Category: Nagar, B.]] | ||
| - | [[Category: Seeliger, M | + | [[Category: Seeliger, M A.]] |
[[Category: GOL]] | [[Category: GOL]] | ||
[[Category: STI]] | [[Category: STI]] | ||
| Line 27: | Line 27: | ||
[[Category: src]] | [[Category: src]] | ||
| - | ''Page seeded by [http:// | + | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 18:19:00 2008'' |
Revision as of 16:19, 21 February 2008
|
Crystal Structure of chicken c-Src kinase domain in complex with the cancer drug imatinib.
Overview
The cancer drug imatinib inhibits the tyrosine kinases c-Abl, c-Kit, and the PDGF receptor. Imatinib is less effective against c-Src, which is difficult to understand because residues interacting with imatinib in crystal structures of Abl and c-Kit are conserved in c-Src. The crystal structure of the c-Src kinase domain in complex with imatinib closely resembles that of Abl*imatinib and c-Kit*imatinib, and differs significantly from the inactive "Src/CDK" conformation of the Src family kinases. Attempts to increase the affinity of c-Src for imatinib by swapping residues with the corresponding residues in Abl have not been successful, suggesting that the thermodynamic penalty for adoption of the imatinib-binding conformation by c-Src is distributed over a broad region of the structure. Two mutations that are expected to destabilize the inactive Src/CDK conformation increase drug sensitivity 15-fold, suggesting that the free-energy balance between different inactive states is a key to imatinib binding.
About this Structure
2OIQ is a Single protein structure of sequence from Gallus gallus with and as ligands. Active as Non-specific protein-tyrosine kinase, with EC number 2.7.10.2 Full crystallographic information is available from OCA.
Reference
c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty., Seeliger MA, Nagar B, Frank F, Cao X, Henderson MN, Kuriyan J, Structure. 2007 Mar;15(3):299-311. PMID:17355866
Page seeded by OCA on Thu Feb 21 18:19:00 2008
Categories: Gallus gallus | Non-specific protein-tyrosine kinase | Single protein | Cao, X. | Frank, F. | Henderson, M N. | Kuriyan, J. | Nagar, B. | Seeliger, M A. | GOL | STI | Imatinib | Inactive | Kinase | Src
